Study of LAD603 for adults with severe alopecia areata
Part of Skin clinical trials.
This trial tests a new medication called LAD603 for people with severe to very severe alopecia areata, a condition causing significant hair loss. It aims to see if the drug can help regrow hair.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have at least 50% scalp hair loss that has not started to grow back in the last 6 months.
- Your current hair loss episode must have lasted between 6 months and 7 years.
- You must not have other types of hair loss (like traction or scarring alopecia) or a 'diffuse' form of alopecia areata.
- You must not have active skin conditions (like psoriasis or lupus) that could interfere with the study.
- You must have normal liver function based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called LY4005130 can help regrow hair in adults with severe alopecia areata (an autoimmune condition causing patchy or widespread hair loss). The trial is looking for people who have lost a significant amount of hair and haven't seen it grow back on its own for at least 6 months.
This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This trial tests an experimental tablet for teenagers with severe alopecia areata, a condition causing patchy hair loss. The treatment may help regrow hair with clearer information about safety and effectiveness.
This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.
This study tests an experimental oral tablet for severe alopecia areata, a condition that causes patches of hair to fall out. The goal is to see if it can help regrow hair safely. You may be able to join if you have this type of hair loss and meet the health requirements.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.